Inovio Covid-19 vaccine candidate was generally safe and well-tolerated. Credit: NIH.

Inovio Pharmaceuticals has reported positive interim results from the initial two cohorts in Phase I clinical trial of its Covid-19 vaccine candidate, INO-4800.

With funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Phase I trial initially recruited 40 healthy adults aged 18 to 50 years at two sites in the US. Participants were given two 1mg or 2mg doses of INO-4800 four weeks apart.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An analysis by independent Data Safety Monitoring Board showed that the Inovio Covid-19 vaccine candidate was generally safe and well-tolerated in all participants across both cohorts through week 8.

The company added that all ten reported adverse events (AEs) were grade 1 in severity, without any serious adverse events (SAEs).

Immunology assays, including tests for humoral and cellular immune responses, are being performed for both INO-4800 dose cohorts following two doses at week 6.

So far, preliminary data on humoral and T cell immune responses has revealed that 94% of total participants experienced overall immunological response rates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Apart from the positive interim Phase I results, the company announced that INO-4800 was able to protect mice in SARS-CoV-2 viral challenge studies, where the vaccine candidate prevented viral replication in the lungs of animals.

Furthermore, INO-4800 has been chosen to be part of a non-human primate (NHP) challenge study under the US Government’s Operation Warp Speed programme.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion of INO-4800 in Operation Warp Speed.

“We are also pleased that INO-4800 vaccination abrogated viral replication in the lungs of mice challenged with SARS-CoV-2.”

The company has expanded the Phase I trial to include older participants in additional cohorts. It also intends to launch a Phase II/III efficacy trial in the coming months.